Undisclosed STAT6 Antagonist / Arcus Biosciences - LARVOL DELTA

Immunology Portfolio (Businesswire) - "Additional Targets: Arcus is advancing additional programs across its immunology portfolio. Arcus’s programs for a small-molecule CCR6 antagonist for psoriasis and inflammatory bowel disease, a STAT6 small molecule program for atopic dermatitis and asthma, a CD89 monoclonal antibody program for the treatment of rheumatoid arthritis, and a CD40L small molecule program for the treatment of multiple sclerosis and systemic lupus erythematosus, are each expected to deliver IND-ready candidates by the end of 2027."

Pipeline update • Asthma • Atopic Dermatitis • Immunology • Multiple Sclerosis • Psoriasis • Rheumatoid Arthritis • Systemic Lupus Erythematosus